Acute Ischemic Stroke Drugs Market to Reach $16.87 Billion by 2028 with 5.4% CAGR, Driven by Emerging Therapies

The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Acute Ischemic Stroke Drugs Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $16.87 billion In 2028 At A CAGR Of 5.4%:
The acute ischemic stroke drugs market size has grown strongly in recent years. It will grow from $13.01 billion in 2023 to $13.66 billion in 2024 at a compound annual growth rate (CAGR) of 5.0%. The growth in the historic period can be attributed to increasing incidence of stroke, government initiatives and healthcare policies, increased awareness and education, strategic collaborations and partnerships, aging population.

The acute ischemic stroke drugs market size is expected to see strong growth in the next few years. It will grow to $16.87 billion in 2028 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to emerging therapies and drug pipeline, precision medicine and personalized therapies, global healthcare infrastructure development, increasing healthcare expenditure, telemedicine and remote patient monitoring. Major trends in the forecast period include advancements in thrombolytic therapies, neuroprotective agents development, personalized medicine and biomarker research, telemedicine and remote monitoring, collaborations and strategic partnerships.

Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=10049&type=smp

Acute Ischemic Stroke Drugs Market Major Segments
The acute ischemic stroke drugs market covered in this report is segmented -
1) By Type: Tablet, Capsule, Other Types
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Hospitals, Diagnostic Centers, Other Applications

Key Driver - Chronic Disease Epidemic Is A Catalyst For The Surge In Acute Ischemic Stroke Drug Market Growth
The rise in the prevalence of chronic diseases is anticipated to propel the growth of the acute ischemic stroke drug market in the coming years. Chronic diseases, also known as non-communicable diseases, refer to conditions that endure for a year or longer and necessitate continuing medical care, restrict everyday activities, or both. The primary causes of death and disability are chronic illnesses such as heart disease, cancer, and diabetes. Acute ischemic stroke drugs are primarily used in chronic diseases to reduce the chances of clot formation and strokes and restore blood flow to the brain. For instance, in September 2022, according to the reports shared by the World Health Organization (WHO), a Switzerland-based health agency, due to chronic diseases, it is estimated 41 million people die each year, which is equivalent to 74% of all deaths globally, and 17 million individuals die before the age of 70 from chronic diseases. By 2025, an estimated 164 million Americans, or nearly 49% of the population, would be living with chronic illnesses. Therefore, the rise in the prevalence of chronic diseases is driving the growth of the acute ischemic stroke drug market.

Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=10049&type=smp

Prominent Trend - Strategic Clinical Advancements Is A Catalyst For Progress In The Acute Ischemic Stroke Drugs Market

Strategic clinical development is a key trend gaining popularity in the acute ischemic stroke drugs market. Major companies operating in the acute ischemic stroke drugs market are focusing on clinical developments to sustain their position in the market. For instance, in May 2021, Biogen Inc., a US-based biotechnology company, purchased the investigational drug TMS-007 for acute ischemic stroke. TMS-007 has the potential to be a next-generation thrombolytic with improved benefits and risk profile. The TMS-007 Phase 2a study also demonstrated positive impacts on blood vessel reopening and patient functional recovery with no incidence of symptomatic intracranial hemorrhage.

Acute Ischemic Stroke Drugs Market Players
Major companies operating in the acute ischemic stroke drugs market report are F. Hoffmann-La Roche AG, C.H. Boehringer Sohn AG & Co. KG, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, AstraZeneca plc, ZZ Biotech LLC, NoNO Inc., Biogen Inc., Athersys Inc., Bayer AG, Sanofi S.A., Pfizer Inc., DiaMedica Therapeutics, Lumosa Therapeutics Co. Ltd., Johnson & Johnson, Acticor Biotech, Meridigen Biotech Co., Prolong Pharmaceuticals LLC, Nanjing Yoko Biomedical Co. Ltd., TrueBinding Inc., GNT Pharma Co. Ltd., aptaTargets SL, NuvOX Pharma, Simcere Pharmaceutical Co. Ltd., Genentech Inc., Pharming Technologies B.V., SanBio BV, Revalesio Corporation, Stemedica Cell Technologies Inc., CorInnova Incorporated, Phagenesis, Aidoc Medical

View The Full Report Here - https://www.thebusinessresearchcompany.com/report/acute-ischemic-stroke-drugs-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the acute ischemic stroke drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global acute ischemic stroke drugs market report during the forecast period. The regions covered in the acute ischemic stroke drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Acute Ischemic Stroke Drugs Market Report Structure
3. Acute Ischemic Stroke Drugs Market Trends And Strategies
4. Acute Ischemic Stroke Drugs Market - Macro Economic Scenario
5. Acute Ischemic Stroke Drugs Market Size And Growth
…..
27. Acute Ischemic Stroke Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.